The therapeutic potential of resolvins in pulmonary diseases.

The therapeutic potential of resolvins in pulmonary diseases.

Publication date: Sep 22, 2023

Uncontrolled inflammation leads to nonspecific destruction and remodeling of tissues and can contribute to many human pathologies, including pulmonary diseases. Stimulation of inflammatory resolution is considered an important process that protects against the progression of chronic inflammatory diseases. Resolvins generated from essential omega-3 polyunsaturated fatty acids have been demonstrated to be signaling molecules in inflammation with important pro-resolving and anti-inflammatory capabilities. By binding to specific receptors, resolvins can modulate inflammatory processes such as neutrophil migration, macrophage phagocytosis and the presence of pro-inflammatory mediators to reduce inflammatory pathologies. The discovery of these pro-resolving mediators has led to a shift in drug research from suppressing pro-inflammatory molecules to investigating compounds that promote resolution to treat inflammation. The exploration of inflammatory resolution also provided the opportunity to further understand the pathophysiology of pulmonary diseases. Alterations of resolution are now linked to both the development and exacerbation of diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, acute respiratory distress syndrome, cancer and COVID-19. These findings have resulted in the rise of novel design and testing of innovative resolution-based therapeutics to treat diseases. Hence, this paper reviews the generation and mechanistic actions of resolvins and investigates their role and therapeutic potential in several pulmonary diseases that may benefit from resolution-based pharmaceuticals.

Concepts Keywords
Pathophysiology Inflammation
Pharmaceuticals Inflammatory resolution
Pro Pro-resolving mediator
Pulmonary Pulmonary disease
Remodeling Resolvin


Type Source Name
disease MESH pulmonary diseases
disease MESH inflammation
disease IDO process
drug DRUGBANK Omega-3 fatty acids
disease MESH asthma
pathway KEGG Asthma
disease MESH chronic obstructive pulmonary disease
disease MESH cystic fibrosis
disease MESH acute respiratory distress syndrome
disease MESH cancer
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)